Summary of COVID-19 siltuximab studies

1. Declercq et al., Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial

149 patient siltuximab late treatment RCT: 64% higher mortality (p=0.27).
RCT 342 hospitalized COVID-19 patients with hypoxia and signs of cytokine release syndrome in Belgium, showing no significant difference in time to clinical improvement, mortality, or other outcomes with IL-1 blockade (anakinra) or IL-6 blockade (siltuximab, tocilizumab) compared to standard of care.
Dec 2021, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260021003775, https://c19p.org/declercq